CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced the presentation of data from studies evaluating a Toll-Like Receptor (TLR) antagonist in a preclinical model of multiple sclerosis (MS). The presentation entitled “Studies of Oligonucleotide-Based Antagonists of TLR9 in a Mouse Model of Experimental Autoimmune Encephalomyelitis” (Abstract #2049) was made during the 60th Annual Meeting of the American Academy of Neurology being held in Chicago, IL, April 12-19, 2008. The presentation was made in Session S50: Multiple Sclerosis: Immunology III.
